MarketBeat
10 Oct 2026, 14:36 UTC · 4h ago
Impact · against what's priced in
The article provides no new catalysts or material updates that would shift the current valuations of IVA, LRMR, or AAPG. The mentioned Phase 3 timelines, BLA submissions, and revenue growth are already reflected in the stocks' risk profiles and analyst price targets.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish · 0 new · 4 priced in
Inventiva expects topline results for its Phase 3 NATiV3 trial of lanifibranor in Q4 2026.
Priced inanalysis of pipeline milestones
So whatPositive data would enable a U.S. regulatory submission in H1 2027, potentially transitioning the firm from pre-revenue to commercial.
More positive than 99% of claims this week
Larimar Therapeutics submitted the first module of its rolling Biologics License Application for nomlabofusp on June 29.
Continue reading
5 related stories
The market is already aware of the Q4 2026 topline results for the NATiV3 trial and the potential for a 2027 regulatory submission, making these known milestones rather than new catalysts.
Read from the article alone
No priced-in read yet
The reported H1 2026 revenue growth of 29% is historical data that does not alter the forward-looking investment thesis.
Read from the article alone
No priced-in read yet
The rolling BLA submission initiated on June 29 and the expectation of full submission by year-end 2026 are already factored into the current analyst outlook.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
Priced inannouncement dated June 29
So whatFull submission is expected by year-end 2026, which is the critical path for obtaining accelerated FDA approval.
More positive than 98% of claims this week
Ascentage Pharma reported H1 2026 revenue of $44.5 million, a 29% increase year over year.
Priced inearnings release dated Aug 19
More positive than 79% of claims this week
Inventiva's annual net losses grew from $34 million in 2019 to $416 million in 2025.
Priced inanalysis of historical financial data
So whatThe steepening loss trajectory suggests significant cash burn that may require dilutive financing before the 2027 submission.
More negative than 77% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Strong analyst buy ratings and triple-digit upside potential despite pre-revenue losses.
More positive than 77% of ticker scores this week
Positive progress with FDA BLA submission and significant analyst price target upside.
More positive than 71% of ticker scores this week
Revenue growth of 29% and strong analyst upside targets, despite poor recent share performance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
—
AAPG hasn't traded since this ran. Last close $14.75 (Oct 9); the reaction starts at the next open.
AAPG chart →—
IVA hasn't traded since this ran. Last close $3.16 (Oct 9); the reaction starts at the next open.
IVA chart →—
LRMR hasn't traded since this ran. Last close $2.67 (Oct 9); the reaction starts at the next open.
LRMR chart →
